JP2023522124A5 - - Google Patents
Info
- Publication number
- JP2023522124A5 JP2023522124A5 JP2022563872A JP2022563872A JP2023522124A5 JP 2023522124 A5 JP2023522124 A5 JP 2023522124A5 JP 2022563872 A JP2022563872 A JP 2022563872A JP 2022563872 A JP2022563872 A JP 2022563872A JP 2023522124 A5 JP2023522124 A5 JP 2023522124A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- independently selected
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20170641.3 | 2020-04-21 | ||
| EP20170641.3A EP3901151B1 (en) | 2020-04-21 | 2020-04-21 | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
| PCT/EP2021/060338 WO2021214117A1 (en) | 2020-04-21 | 2021-04-21 | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522124A JP2023522124A (ja) | 2023-05-26 |
| JP2023522124A5 true JP2023522124A5 (enExample) | 2024-04-18 |
Family
ID=71108343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563872A Pending JP2023522124A (ja) | 2020-04-21 | 2021-04-21 | ハロゲン化ヘテロアリール及び他のヘテロ環系キナーゼ阻害剤、及びその用途 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230348453A1 (enExample) |
| EP (2) | EP3901151B1 (enExample) |
| JP (1) | JP2023522124A (enExample) |
| KR (1) | KR20230015343A (enExample) |
| CN (1) | CN115667255B (enExample) |
| AU (1) | AU2021258431A1 (enExample) |
| BR (1) | BR112022021476A2 (enExample) |
| CA (1) | CA3176325A1 (enExample) |
| CL (1) | CL2022002899A1 (enExample) |
| CO (1) | CO2022016245A2 (enExample) |
| CR (1) | CR20220528A (enExample) |
| IL (1) | IL297481A (enExample) |
| MX (1) | MX2022013160A (enExample) |
| PE (1) | PE20230462A1 (enExample) |
| PH (1) | PH12022552813A1 (enExample) |
| TW (1) | TW202204352A (enExample) |
| WO (1) | WO2021214117A1 (enExample) |
| ZA (1) | ZA202212631B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020051424A1 (en) | 2018-09-07 | 2020-03-12 | Pic Therapeutics | Eif4e inhibitors and uses thereof |
| TW202146393A (zh) | 2020-03-03 | 2021-12-16 | 美商皮克醫療公司 | Eif4e抑制劑及其用途 |
| CA3229560A1 (en) | 2021-08-25 | 2023-03-02 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| JP2024539268A (ja) * | 2021-10-19 | 2024-10-28 | アイオーエムエックス セラピューティクス アーゲー | Ｓｉｋ３阻害剤及びその中間体を調製する合成スキーム及び手順 |
| US12116597B2 (en) * | 2022-01-05 | 2024-10-15 | The Board Of Regents Of The University Of Texas System | Autophagy as a therapeutic target for intracranial aneurysm |
| EP4257132A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Sik3 inhibitors for treating diseases resistant to death receptor signalling |
| EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
| EP4643861A1 (en) | 2024-04-30 | 2025-11-05 | iOmx Therapeutics AG | A halogenated-heteroaryl kinase inhbitor for treating soft tissue sarcoma and vascular tumors |
| WO2025229127A1 (en) | 2024-04-30 | 2025-11-06 | Iomx Therapeutics Ag | A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4475916A (en) | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| IL153246A0 (en) * | 2000-06-28 | 2003-07-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| WO2006081172A2 (en) | 2005-01-26 | 2006-08-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US20100113520A1 (en) * | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CN103172627B (zh) * | 2011-12-26 | 2015-11-18 | 南京优科生物医药有限公司 | 杂环嘧啶苯或吡啶苯类化合物及其应用 |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| CA2955082A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
| CN106699744B (zh) * | 2015-11-18 | 2021-05-11 | 四川海思科制药有限公司 | 一种杂环类酰胺衍生物及其制备方法和在药学上的应用 |
| AU2018226771B2 (en) | 2017-02-28 | 2023-11-23 | Dana-Farber Cancer Institute, Inc. | Uses of pyrimidopyrimidinones as SIK inhibitors |
| EP3391907B8 (en) | 2017-04-20 | 2020-03-04 | iOmx Therapeutics AG | Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof |
| DK3643713T3 (da) * | 2018-10-23 | 2025-11-03 | Iomx Therapeutics Ag | Heterocykliske kinaseinhibitorer og deres anvendelse |
-
2020
- 2020-04-21 EP EP20170641.3A patent/EP3901151B1/en active Active
-
2021
- 2021-04-21 IL IL297481A patent/IL297481A/en unknown
- 2021-04-21 CN CN202180027921.5A patent/CN115667255B/zh active Active
- 2021-04-21 JP JP2022563872A patent/JP2023522124A/ja active Pending
- 2021-04-21 AU AU2021258431A patent/AU2021258431A1/en active Pending
- 2021-04-21 CA CA3176325A patent/CA3176325A1/en active Pending
- 2021-04-21 KR KR1020227040346A patent/KR20230015343A/ko active Pending
- 2021-04-21 US US17/996,514 patent/US20230348453A1/en active Pending
- 2021-04-21 MX MX2022013160A patent/MX2022013160A/es unknown
- 2021-04-21 TW TW110114388A patent/TW202204352A/zh unknown
- 2021-04-21 BR BR112022021476A patent/BR112022021476A2/pt unknown
- 2021-04-21 PH PH1/2022/552813A patent/PH12022552813A1/en unknown
- 2021-04-21 EP EP21718920.8A patent/EP4139305A1/en active Pending
- 2021-04-21 WO PCT/EP2021/060338 patent/WO2021214117A1/en not_active Ceased
- 2021-04-21 CR CR20220528A patent/CR20220528A/es unknown
- 2021-04-21 PE PE2022002448A patent/PE20230462A1/es unknown
-
2022
- 2022-10-20 CL CL2022002899A patent/CL2022002899A1/es unknown
- 2022-11-11 CO CONC2022/0016245A patent/CO2022016245A2/es unknown
- 2022-11-21 ZA ZA2022/12631A patent/ZA202212631B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023522124A5 (enExample) | ||
| IL297481A (en) | Halogenated heteroaryls and other heterocyclic kinase inhibitors, and uses thereof | |
| US12268666B2 (en) | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | |
| US10654831B2 (en) | Antiproliferative pyrimidine-based compounds | |
| US20250289818A1 (en) | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer | |
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| IL298300A (en) | 4-oxo-3,4-dihydroquinazolinone compounds for the treatment of braf-related diseases and disorders | |
| JP2022501431A (ja) | Ｓｒｃホモロジー−２ホスファターゼ阻害剤としての縮合三環式環誘導体 | |
| US20240115571A1 (en) | Combination therapy for treating abnormal cell growth | |
| JP2020002146A (ja) | イブルチニブ併用療法 | |
| WO2022221227A9 (en) | Amino-substituted heterocycles for treating cancers with egfr mutations | |
| CN120887906A (zh) | 用于靶蛋白降解的螺环降解决定子体 | |
| JP2018527398A (ja) | ヘテロ環式化合物およびそれらの使用 | |
| AU2017286654A1 (en) | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | |
| JP2022536540A (ja) | アミノピリミジンアミドオートファジー阻害剤およびその使用方法 | |
| TW202529768A (zh) | 癌症治療的療法 | |
| JP2020183445A (ja) | 医薬組成物 | |
| JP2018509442A (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| TW202116770A (zh) | 類鐸受體促效劑 | |
| AU2019408244B2 (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| EP1885187B1 (en) | Methods for treating drug resistant cancer | |
| JP2024529453A (ja) | 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用 | |
| RU2022129897A (ru) | Галогенированные гетероарильные и другие гетероциклические ингибиторы киназы и их применение | |
| JPWO2018186366A1 (ja) | 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤 | |
| US12162876B2 (en) | Indazole kinase inhibitor and use thereof |